Bas P. L. Wijnhoven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bas P. L. Wijnhoven has a total of 476 co-authors. Here are the top co-authors by number of shared publications:
- Richard van Hillegersberg
Department of Surgery, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
9 shared publications Sjoerd M Lagarde
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center , Rotterdam
9 shared publications- Ben M. Eyck
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
8 shared publications - Gelde Arie Pieter Nieuwenhuijzen
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands
8 shared publications - Magnus Nilsson
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden
7 shared publications - Mark Ivo van Berge Henegouwen
Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands
7 shared publications
Latest Publications
- 2 September 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (5)
The current management of Boerhaave syndrome—a European multicenter case-vignette study
SUMMARY: Boerhaave syndrome is a rare surgical emergency, defined as a spontaneous perforation of the esophagus. Treatment options include endoscopic intervention and/or surgery, but the morbidity and mortality associated with Boerhaave syndrome is high. No consensus-based treatment guidelines currently exist. The aim of this study was to evaluate the diversity in treatment strategies for different clinical scenarios of Boerhaave syndrome across Europe. Forty-four surgeons from 24 different esophageal tertiary centers across nine European countries, Australia and the United Kingdom were invited to participate in this case-vignette study. Each surgeon was presented with four different cases of patients with Boerhaave syndrome and asked for their choice of initial treatment using a multiple-choice questionnaire. A multivariable regression analysis was performed to identify predictors of treatment choice. Thirty-one surgeons from 21 centers (20 in Europe across 9 countries and 1 in Australia) participated in the study. The proportion of surgeons selecting endoscopic treatment varied across the four cases (45%–84%, P < 0.01). Endoscopic treatment was associated with younger patient age (OR 0.83, 95% CI [0.75, 0.92], P < 0.01), absence of sepsis (OR 0.11, 95% CI [0.00, 0.16], P < 0.01) and increased time to treatment (OR 1.97, 95% CI [1.17, 3.31], P = 0.01). All surgeons working at Nordic centers (N = 6) exclusively opted for endoscopic treatment. We found considerable diversity in treatment strategies among surgeons presented with identical cases of patients with Boerhaave syndrome. Notably, all surgeons working at a Nordic center selected endoscopic treatment as their initial treatment strategy in all four cases.
- 2 September 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (5)
The current management of Boerhaave syndrome—a European multicenter case-vignette study
SUMMARY: Boerhaave syndrome is a rare surgical emergency, defined as a spontaneous perforation of the esophagus. Treatment options include endoscopic intervention and/or surgery, but the morbidity and mortality associated with Boerhaave syndrome is high. No consensus-based treatment guidelines currently exist. The aim of this study was to evaluate the diversity in treatment strategies for different clinical scenarios of Boerhaave syndrome across Europe. Forty-four surgeons from 24 different esophageal tertiary centers across nine European countries, Australia and the United Kingdom were invited to participate in this case-vignette study. Each surgeon was presented with four different cases of patients with Boerhaave syndrome and asked for their choice of initial treatment using a multiple-choice questionnaire. A multivariable regression analysis was performed to identify predictors of treatment choice. Thirty-one surgeons from 21 centers (20 in Europe across 9 countries and 1 in Australia) participated in the study. The proportion of surgeons selecting endoscopic treatment varied across the four cases (45%–84%, P < 0.01). Endoscopic treatment was associated with younger patient age (OR 0.83, 95% CI [0.75, 0.92], P < 0.01), absence of sepsis (OR 0.11, 95% CI [0.00, 0.16], P < 0.01) and increased time to treatment (OR 1.97, 95% CI [1.17, 3.31], P = 0.01). All surgeons working at Nordic centers (N = 6) exclusively opted for endoscopic treatment. We found considerable diversity in treatment strategies among surgeons presented with identical cases of patients with Boerhaave syndrome. Notably, all surgeons working at a Nordic center selected endoscopic treatment as their initial treatment strategy in all four cases.
- 27 August 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (9)
Standard reporting on duodenal stump leakage after gastric cancer resections: multicentre analysis from the GASTRODATA Study Group (the STARDUST study)
Background: Gastric cancer surgery has historically implied significant levels of clinical burden and mortality. Postoperative duodenal stump leakage (DSL) represents a leading cause of postoperative mortality, but international occurrence rates and treatment strategy are lacking. The aim of this multinational retrospective cohort study was to evaluate the occurrence rate and treatment strategy factors for duodenal stump leakage after gastrectomy for cancer. Methods: This retrospective multinational multicentre cohort study (the STARDUST study) retrospectively analysed a consecutive series of gastric cancer patients who underwent gastrectomy from 2019 to 2022 at 24 high-volume European members of the GASTRODATA registry. The primary outcomes included postoperative incidence and 90-day mortality after DSL. Secondary outcomes were clinical presentation, perioperative determinants, and complication treatment. Results: A total of 2558 consecutive gastric cancer patients were identified from the registry and 2422 were eligible for the study. DSL occurred in 2.6% (64 of 2422) of the patients with a subsequent 90-day mortality rate of 17.2% (11 of 64). Conservative treatment was used for nine patients, followed by successful recovery without readmission. Interventional radiology was used for 16 patients (treatment success rate of 75%), while 39 patients required reoperation for acute presentation or failure of conservative options (treatment success rate of 74.4%). Multivariate analysis identified statistically significant independent prognostic factors for DSL, including preoperative weight loss, unreinforced duodenal stump, Billroth II reconstruction, and postoperative blood transfusion. Conclusion: Postoperative DSL was uncommon (2.6%), but it was associated with a 90-day mortality rate of 17.2%, which varied according to the severity of the clinical presentation and the invasiveness of the treatment. Preoperative weight loss, unreinforced duodenal stump, Billroth II reconstruction, and postoperative blood transfusion were prognostic factors associated with complication occurrence. The results need to be validated and prospectively endorsed within a standardized protocol guiding the intraoperative management of the duodenal stump and the choice of complication treatment.
- 27 August 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (9)
Standard reporting on duodenal stump leakage after gastric cancer resections: multicentre analysis from the GASTRODATA Study Group (the STARDUST study)
Background: Gastric cancer surgery has historically implied significant levels of clinical burden and mortality. Postoperative duodenal stump leakage (DSL) represents a leading cause of postoperative mortality, but international occurrence rates and treatment strategy are lacking. The aim of this multinational retrospective cohort study was to evaluate the occurrence rate and treatment strategy factors for duodenal stump leakage after gastrectomy for cancer. Methods: This retrospective multinational multicentre cohort study (the STARDUST study) retrospectively analysed a consecutive series of gastric cancer patients who underwent gastrectomy from 2019 to 2022 at 24 high-volume European members of the GASTRODATA registry. The primary outcomes included postoperative incidence and 90-day mortality after DSL. Secondary outcomes were clinical presentation, perioperative determinants, and complication treatment. Results: A total of 2558 consecutive gastric cancer patients were identified from the registry and 2422 were eligible for the study. DSL occurred in 2.6% (64 of 2422) of the patients with a subsequent 90-day mortality rate of 17.2% (11 of 64). Conservative treatment was used for nine patients, followed by successful recovery without readmission. Interventional radiology was used for 16 patients (treatment success rate of 75%), while 39 patients required reoperation for acute presentation or failure of conservative options (treatment success rate of 74.4%). Multivariate analysis identified statistically significant independent prognostic factors for DSL, including preoperative weight loss, unreinforced duodenal stump, Billroth II reconstruction, and postoperative blood transfusion. Conclusion: Postoperative DSL was uncommon (2.6%), but it was associated with a 90-day mortality rate of 17.2%, which varied according to the severity of the clinical presentation and the invasiveness of the treatment. Preoperative weight loss, unreinforced duodenal stump, Billroth II reconstruction, and postoperative blood transfusion were prognostic factors associated with complication occurrence. The results need to be validated and prospectively endorsed within a standardized protocol guiding the intraoperative management of the duodenal stump and the choice of complication treatment.
- 2 July 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (4)
Reasons for hospital readmissions after esophagectomy for cancer
Summary: While postoperative complications are established predictors of readmission after esophagectomy, reasons for readmission are still elusive, specifically in patients without complications during the index admission. This study assessed reasons for readmission and explored potential predictors in this lower-risk subgroup. A retrospective multicenter cohort study included all patients ≥18 years who underwent curative esophagectomy between 2020 and 2023 across three Dutch hospitals. Patients with in-hospital mortality or missing readmission data were excluded. The primary outcome was the reason for 30-day readmission. Secondary outcome was the identification of risk factors for readmission using uni- and multivariable logistic regression. Of 663 patients, 350 (52.8%) had an uncomplicated index admission, with a 30-day readmission rate of 12.6% (44/350). The most common causes for readmission were anastomotic leakage (32.6%), pulmonary complications (20.9%), insufficient intake (14.0%), and infections (14.0%). No significant associations were found with age, sex, the American Society of Anesthesiologists (ASA) classification, Charlson Comorbidity Index, tube feeding, length of stay, or surgical approach. Among patients readmitted with anastomotic leakage, 11/14 had met functional recovery criteria at discharge. Three patients had unexplained subtle increases in C-reactive protein (CRP) or leukocyte count. Three patients underwent a computed tomography (CT) scan during the index admission. Readmission remains common, even in patients with an initially uneventful recovery, and is frequently caused by undetected or delayed complications including anastomotic leakage. Traditional predictors did not identify patients at risk for readmission in this cohort. Subtle deviations before discharge may represent early warning signs and require validation in future prospective research.
- 2 July 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (4)
Reasons for hospital readmissions after esophagectomy for cancer
Summary: While postoperative complications are established predictors of readmission after esophagectomy, reasons for readmission are still elusive, specifically in patients without complications during the index admission. This study assessed reasons for readmission and explored potential predictors in this lower-risk subgroup. A retrospective multicenter cohort study included all patients ≥18 years who underwent curative esophagectomy between 2020 and 2023 across three Dutch hospitals. Patients with in-hospital mortality or missing readmission data were excluded. The primary outcome was the reason for 30-day readmission. Secondary outcome was the identification of risk factors for readmission using uni- and multivariable logistic regression. Of 663 patients, 350 (52.8%) had an uncomplicated index admission, with a 30-day readmission rate of 12.6% (44/350). The most common causes for readmission were anastomotic leakage (32.6%), pulmonary complications (20.9%), insufficient intake (14.0%), and infections (14.0%). No significant associations were found with age, sex, the American Society of Anesthesiologists (ASA) classification, Charlson Comorbidity Index, tube feeding, length of stay, or surgical approach. Among patients readmitted with anastomotic leakage, 11/14 had met functional recovery criteria at discharge. Three patients had unexplained subtle increases in C-reactive protein (CRP) or leukocyte count. Three patients underwent a computed tomography (CT) scan during the index admission. Readmission remains common, even in patients with an initially uneventful recovery, and is frequently caused by undetected or delayed complications including anastomotic leakage. Traditional predictors did not identify patients at risk for readmission in this cohort. Subtle deviations before discharge may represent early warning signs and require validation in future prospective research.
- Open Access
- 23 March 2026
- Published by Elsevier in SSRN Electronic Journal
The challenge of informed consent: propensity score matching to prevent selection bias
SummaryInformed consent requirements can introduce significant selection bias. This note evaluates prospective versus retrospective consent models and the utility of propensity score matching to reduce selection bias. While statistical adjustments mitigate the bias, upfront consent frameworks are essential for ensuring unbiased population estimates.
- 23 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe challenge of informed consent: propensity score matching to prevent selection bias
SummaryInformed consent requirements can introduce significant selection bias. This note evaluates prospective versus retrospective consent models and the utility of propensity score matching to reduce selection bias. While statistical adjustments mitigate the bias, upfront consent frameworks are essential for ensuring unbiased population estimates.
- Open Access
- 17 March 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (4)
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements
Background: Gastric cancer peritoneal metastasis (GCPM) is a common manifestation of advanced gastric cancer, associated with poor prognosis. Methods: The International Gastric Cancer Association (IGCA) convened a multidisciplinary working group of 42 global experts from 15 countries to develop a total of 13 consensus statements addressing diagnosis, treatment, and research priorities for GCPM. Using ACcurate COnsensus Reporting Document (ACCORD)-compliant methodology, the group conducted systematic literature searches and applied a structured Delphi process with anonymous Likert-scale voting and a ≥70% consensus threshold to generate and refine consensus statements. Results: Consensus was achieved for all 13 statements among the working group during the first Delphi round, with 75–100% of respondents selecting either ‘strongly agree’ or ‘agree’. Coefficient of variation values were ≤0.23. Polling of a broader group of experts (n = 66), which included members of the working group (n = 21), during a GCPM consensus session at the 16th International Gastric Cancer Congress (IGCC) in 2025 demonstrated agreement for 12 of the 13 statements. This broader group of experts, which had greater representation from medical oncologists, did not reach consensus (52% agreement) on best practice for systemic treatment of patients with GCPM, possibly due to the rapidly evolving developments in this field of metastatic gastric cancer. Conclusion: This consensus exercise provides a foundation for globally relevant GCPM management strategies and highlights critical research needed to address significant evidence gaps that will improve patient outcomes.
- 17 March 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (4)
Open AccessManagement of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements
Background: Gastric cancer peritoneal metastasis (GCPM) is a common manifestation of advanced gastric cancer, associated with poor prognosis. Methods: The International Gastric Cancer Association (IGCA) convened a multidisciplinary working group of 42 global experts from 15 countries to develop a total of 13 consensus statements addressing diagnosis, treatment, and research priorities for GCPM. Using ACcurate COnsensus Reporting Document (ACCORD)-compliant methodology, the group conducted systematic literature searches and applied a structured Delphi process with anonymous Likert-scale voting and a ≥70% consensus threshold to generate and refine consensus statements. Results: Consensus was achieved for all 13 statements among the working group during the first Delphi round, with 75–100% of respondents selecting either ‘strongly agree’ or ‘agree’. Coefficient of variation values were ≤0.23. Polling of a broader group of experts (n = 66), which included members of the working group (n = 21), during a GCPM consensus session at the 16th International Gastric Cancer Congress (IGCC) in 2025 demonstrated agreement for 12 of the 13 statements. This broader group of experts, which had greater representation from medical oncologists, did not reach consensus (52% agreement) on best practice for systemic treatment of patients with GCPM, possibly due to the rapidly evolving developments in this field of metastatic gastric cancer. Conclusion: This consensus exercise provides a foundation for globally relevant GCPM management strategies and highlights critical research needed to address significant evidence gaps that will improve patient outcomes.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (2)
Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study
Cervical lymph node metastasis in thoracic esophageal cancer occupies a conceptual border zone between locoregional and distant disease. Evidence guiding treatment selection in this population remains limited in Western cohorts. The objective was to evaluate treatment strategies and overall survival outcomes for patients with resectable esophageal cancer and concurrent cervical lymph node metastasis in the Netherlands. This population-based cohort study used the Netherlands Cancer Registry to identify patients with resectable thoracic esophageal or gastroesophageal junction cancer and concurrent cervical lymph node metastasis. Treatment strategies included definitive chemoradiotherapy, neoadjuvant therapy followed by surgery, chemotherapy with or without limited radiotherapy (≤30 Gy), palliative radiotherapy, and best supportive care. Kaplan–Meier analysis and Cox regression adjusted with inverse probability of treatment weighting (IPTW) were used to assess overall survival and treatment effects. Between 2015 and 2021, 412 eligible patients were identified. Median overall survival was 24 months for patients treated with neoadjuvant therapy followed by surgery, 18 months for definitive chemoradiotherapy, 15 months for chemotherapy, 7 months for radiotherapy alone, and 3 months for best supportive care. In multivariable analysis, neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive chemoradiotherapy (HR 0.56 [0.34–0.91]). Similar estimates were observed after IPTW. Higher cN stage and poorer performance status were independently associated with worse survival. Subgroup analysis of neoadjuvant chemoradiotherapy versus chemotherapy within the surgical cohort showed no significant survival difference. In this nationwide cohort, management of thoracic esophageal cancer with concurrent cervical lymph node metastasis was highly heterogeneous. Although neoadjuvant therapy followed by surgery was associated with longer survival, interpretation is limited by baseline differences and potential residual confounding. These findings suggest that surgery may be considered within a multimodality strategy in carefully selected patients and warrant prospective evaluation to better define its role.
- 2 March 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (2)
Open AccessTreatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study
Cervical lymph node metastasis in thoracic esophageal cancer occupies a conceptual border zone between locoregional and distant disease. Evidence guiding treatment selection in this population remains limited in Western cohorts. The objective was to evaluate treatment strategies and overall survival outcomes for patients with resectable esophageal cancer and concurrent cervical lymph node metastasis in the Netherlands. This population-based cohort study used the Netherlands Cancer Registry to identify patients with resectable thoracic esophageal or gastroesophageal junction cancer and concurrent cervical lymph node metastasis. Treatment strategies included definitive chemoradiotherapy, neoadjuvant therapy followed by surgery, chemotherapy with or without limited radiotherapy (≤30 Gy), palliative radiotherapy, and best supportive care. Kaplan–Meier analysis and Cox regression adjusted with inverse probability of treatment weighting (IPTW) were used to assess overall survival and treatment effects. Between 2015 and 2021, 412 eligible patients were identified. Median overall survival was 24 months for patients treated with neoadjuvant therapy followed by surgery, 18 months for definitive chemoradiotherapy, 15 months for chemotherapy, 7 months for radiotherapy alone, and 3 months for best supportive care. In multivariable analysis, neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive chemoradiotherapy (HR 0.56 [0.34–0.91]). Similar estimates were observed after IPTW. Higher cN stage and poorer performance status were independently associated with worse survival. Subgroup analysis of neoadjuvant chemoradiotherapy versus chemotherapy within the surgical cohort showed no significant survival difference. In this nationwide cohort, management of thoracic esophageal cancer with concurrent cervical lymph node metastasis was highly heterogeneous. Although neoadjuvant therapy followed by surgery was associated with longer survival, interpretation is limited by baseline differences and potential residual confounding. These findings suggest that surgery may be considered within a multimodality strategy in carefully selected patients and warrant prospective evaluation to better define its role.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (2)
ISDE guidelines on the management of cT2N0 esophageal cancer
Esophageal cancer incidence is rising globally, with at least 500,000 new cases diagnosed annually. Management options for non-metastatic disease include primary resection, neoadjuvant or perioperative therapies, or definitive non-surgical treatment, with the choice being guided by tumor staging, histology, patient fitness, and available resources. However, even with the use of advanced diagnostic modalities, preoperative clinical staging is challenging with respect to accuracy of both tumor and nodal assessment. Early-stage esophageal cancer may be managed with local therapies, such as endoscopic mucosal resection or submucosal dissection, while for more advanced tumors managed with curative intent neoadjuvant oncologic therapy is commonly recommended. However, between these two groups lies an infrequent but important subgroup of patients, clinically staged cT2N0M0 esophageal cancer. Guidelines such as the NIH’s National Cancer Institute recommends either surgery alone or neoadjuvant therapy followed by surgery for AJCC Stage I cancers, and add the option of definitive chemoradiation for Stage II disease. With cT2N0 disease straddling both AJCC classifications, management guidance is lacking. This guideline will provide an evidence-based recommendation from the International Society For Disease Of The Esophagus on the management of cT2N0 esophageal cancer, of all types. The recommendations are intended to support surgeons, oncologists, and patients in decisions about the best practice preoperative oncologic management of cT2N0M0 esophageal cancer. A Working Group within the International Society for Diseases of the Esophagus (ISDE) Guidelines Committee performed a systematic review of the literature. Results of the systematic review were presented to a panel of experts and these results informed the panel discussion about the guideline. This panel used Grading of Recommendations Assessment, Development, and Evaluation approach to deliberate and formulate recommendations. The panel agreed on a conditional recommendation for the use of neoadjuvant therapy followed by surgery over primary surgical resection (PSR) for adult patients with cT2N0M0 esophageal cancer. Preoperative clinical staging of esophageal cancer is uncertain, with deficiencies in all diagnostic modalities. However, when all modern staging techniques are utilized, the ISDE recommends neoadjuvant therapy followed by surgical resection as the favored treatment of cT2N0 esophageal cancer. Certain patient groups may still be offered PSR, particularly those unable to tolerate neoadjuvant therapies, or those patients with very low risk of lymph node metastasis as suggested by histological features, small tumor size, and other features.
- 2 March 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (2)
Open AccessISDE guidelines on the management of cT2N0 esophageal cancer
Esophageal cancer incidence is rising globally, with at least 500,000 new cases diagnosed annually. Management options for non-metastatic disease include primary resection, neoadjuvant or perioperative therapies, or definitive non-surgical treatment, with the choice being guided by tumor staging, histology, patient fitness, and available resources. However, even with the use of advanced diagnostic modalities, preoperative clinical staging is challenging with respect to accuracy of both tumor and nodal assessment. Early-stage esophageal cancer may be managed with local therapies, such as endoscopic mucosal resection or submucosal dissection, while for more advanced tumors managed with curative intent neoadjuvant oncologic therapy is commonly recommended. However, between these two groups lies an infrequent but important subgroup of patients, clinically staged cT2N0M0 esophageal cancer. Guidelines such as the NIH’s National Cancer Institute recommends either surgery alone or neoadjuvant therapy followed by surgery for AJCC Stage I cancers, and add the option of definitive chemoradiation for Stage II disease. With cT2N0 disease straddling both AJCC classifications, management guidance is lacking. This guideline will provide an evidence-based recommendation from the International Society For Disease Of The Esophagus on the management of cT2N0 esophageal cancer, of all types. The recommendations are intended to support surgeons, oncologists, and patients in decisions about the best practice preoperative oncologic management of cT2N0M0 esophageal cancer. A Working Group within the International Society for Diseases of the Esophagus (ISDE) Guidelines Committee performed a systematic review of the literature. Results of the systematic review were presented to a panel of experts and these results informed the panel discussion about the guideline. This panel used Grading of Recommendations Assessment, Development, and Evaluation approach to deliberate and formulate recommendations. The panel agreed on a conditional recommendation for the use of neoadjuvant therapy followed by surgery over primary surgical resection (PSR) for adult patients with cT2N0M0 esophageal cancer. Preoperative clinical staging of esophageal cancer is uncertain, with deficiencies in all diagnostic modalities. However, when all modern staging techniques are utilized, the ISDE recommends neoadjuvant therapy followed by surgical resection as the favored treatment of cT2N0 esophageal cancer. Certain patient groups may still be offered PSR, particularly those unable to tolerate neoadjuvant therapies, or those patients with very low risk of lymph node metastasis as suggested by histological features, small tumor size, and other features.
- Top Cited PapersOpen Access
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (3)
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma
Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 113 (3)
Top Cited PapersOpen AccessSurvival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma
Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.
- Open Access
- 9 January 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (1)
International Society for Diseases of the Esophagus consensus on the diagnosis and treatment of anastomotic leak after esophagectomy
SUMMARY: Background: Anastomotic leak (AL) is a severe complication after esophagectomy. Guidelines for the management of AL are lacking. This study aimed to develop a consensus statement for managing AL after esophagectomy. A three-stage modified Delphi study was performed in collaboration with the International Society for Diseases of the Esophagus Guidelines Committee. In Stage 1, a scoping systematic review was performed to identify available literature used to formulate Delphi statements. Stage 2 involved a two-round Delphi survey, distributed globally to surgeons and gastroenterologists. Consensus was defined as ≥80% (strong) (dis)agreement on a Delphi statement. During Stage 3 (guideline development), an international expert panel formulated clinical recommendations based on Delphi consensus and assigned strength in line with Grading of Recommendations Assessment, Development, and Evaluation principles. A clinical care algorithm was developed based on these recommendations. Of 5.843 articles screened, 118 were included to form Delphi statements. The Delphi survey was completed by 106 respondents in the first round and 136 in the second. Based on Delphi consensus and expert panel discussions, 12 diagnostic recommendations were formulated, covering clinical signs, biochemical tests, and imaging strategies. 11 recommendations were formulated regarding treatment strategies, including indications and techniques for supportive care, drainage and defect closure. This led to the development of a clinical care algorithm. A consensus statement for the diagnosis and treatment of AL after esophagectomy was developed. This may aid clinicians in the diagnosis and management of AL and provide a tool for standardizing clinical practice with the aim to improve patient outcomes.
- 9 January 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (1)
Open AccessInternational Society for Diseases of the Esophagus consensus on the diagnosis and treatment of anastomotic leak after esophagectomy
SUMMARY: Background: Anastomotic leak (AL) is a severe complication after esophagectomy. Guidelines for the management of AL are lacking. This study aimed to develop a consensus statement for managing AL after esophagectomy. A three-stage modified Delphi study was performed in collaboration with the International Society for Diseases of the Esophagus Guidelines Committee. In Stage 1, a scoping systematic review was performed to identify available literature used to formulate Delphi statements. Stage 2 involved a two-round Delphi survey, distributed globally to surgeons and gastroenterologists. Consensus was defined as ≥80% (strong) (dis)agreement on a Delphi statement. During Stage 3 (guideline development), an international expert panel formulated clinical recommendations based on Delphi consensus and assigned strength in line with Grading of Recommendations Assessment, Development, and Evaluation principles. A clinical care algorithm was developed based on these recommendations. Of 5.843 articles screened, 118 were included to form Delphi statements. The Delphi survey was completed by 106 respondents in the first round and 136 in the second. Based on Delphi consensus and expert panel discussions, 12 diagnostic recommendations were formulated, covering clinical signs, biochemical tests, and imaging strategies. 11 recommendations were formulated regarding treatment strategies, including indications and techniques for supportive care, drainage and defect closure. This led to the development of a clinical care algorithm. A consensus statement for the diagnosis and treatment of AL after esophagectomy was developed. This may aid clinicians in the diagnosis and management of AL and provide a tool for standardizing clinical practice with the aim to improve patient outcomes.
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (12)
Treatment strategies for Boerhaave syndrome: multinational retrospective cohort study
Background: Boerhaave syndrome is defined as a spontaneous perforation of the oesophagus. The mainstay of treatment is resuscitation of the patient, closure of the oesophageal defect, and drainage of perioesophageal and pleural fluid collections. Whether the optimal approach is endoscopic, surgical, or conservative management remains unknown and there are no clear guidelines. The aim of this multicentre retrospective cohort study was to evaluate current treatment strategies and outcomes for Boerhaave syndrome. Methods: A multicentre retrospective analysis of data from 23 participating European tertiary centres was performed. Patients with Boerhaave syndrome treated between January 2019 and December 2023 were eligible for inclusion. The primary endpoint was the length of ICU stay and secondary endpoints included in-hospital mortality, 90-day mortality, and the length of overall hospital stay. Results: In total, 216 patients were included; 151 were men (70%), the median age was 62 (22–95) years, and 81 (40%) were treated >24 h after the start of symptoms. Seventy (32%) patients were managed endoscopically (group I), 73 (34%) were managed surgically (group II), 67 (31%) were managed using a combination of endoscopy and surgery (group III), and 6 (3%) were managed using other methods (group IV). For patients in groups I–III: the median length of ICU stay was 8 (0–67) days, with no differences between the three groups (P = 0.105); the in-hospital mortality rate and 90-day mortality rate were both 12% (P = 0.490 and P = 0.637, respectively); and the median length of overall hospital stay was 27 (range 1–193) days, with the longest stays observed in patients who received combined treatment (P = 0.032). Conclusion: This study provides a comprehensive overview of the current treatment strategies and outcomes for patients with Boerhaave syndrome in Europe.
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (12)
Treatment strategies for Boerhaave syndrome: multinational retrospective cohort study
Background: Boerhaave syndrome is defined as a spontaneous perforation of the oesophagus. The mainstay of treatment is resuscitation of the patient, closure of the oesophageal defect, and drainage of perioesophageal and pleural fluid collections. Whether the optimal approach is endoscopic, surgical, or conservative management remains unknown and there are no clear guidelines. The aim of this multicentre retrospective cohort study was to evaluate current treatment strategies and outcomes for Boerhaave syndrome. Methods: A multicentre retrospective analysis of data from 23 participating European tertiary centres was performed. Patients with Boerhaave syndrome treated between January 2019 and December 2023 were eligible for inclusion. The primary endpoint was the length of ICU stay and secondary endpoints included in-hospital mortality, 90-day mortality, and the length of overall hospital stay. Results: In total, 216 patients were included; 151 were men (70%), the median age was 62 (22–95) years, and 81 (40%) were treated >24 h after the start of symptoms. Seventy (32%) patients were managed endoscopically (group I), 73 (34%) were managed surgically (group II), 67 (31%) were managed using a combination of endoscopy and surgery (group III), and 6 (3%) were managed using other methods (group IV). For patients in groups I–III: the median length of ICU stay was 8 (0–67) days, with no differences between the three groups (P = 0.105); the in-hospital mortality rate and 90-day mortality rate were both 12% (P = 0.490 and P = 0.637, respectively); and the median length of overall hospital stay was 27 (range 1–193) days, with the longest stays observed in patients who received combined treatment (P = 0.032). Conclusion: This study provides a comprehensive overview of the current treatment strategies and outcomes for patients with Boerhaave syndrome in Europe.